Torna all'elenco degli studi
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREMM14)
CODICE STUDIO
NCT05064358
TIPOLOGIA
Ricaduti
NOME SPONSOR
GlaxoSmithKline
DESCRIZIONE
Trattamento
Experimental: Cohort 1: Participants receiving Belantamab Mafodotin at dose level (DL) 1
Experimental: Cohort 2: Participants receiving Belantamab Mafodotin at DL 2
Leggi tuttoFARMACI UTILIZZATI
Belantamab Mafodotin